CTA313

N/A

Report date: 2025/12/01 11:39:44

Base Information

Drug NameCTA313
Drug Alias NameCTA313
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitorsB-cell maturation protein inhibitors
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsLupus Erythematosus, SystemicNeuromuscular DiseasesRheumatic Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNanjing Bioheng Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Bioheng Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicNeuromuscular DiseasesRheumatic Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A